Tirzepatide for Weight Loss

Participants received lifestyle support and gradual dose escalation. The figures describe group averages from separate trials, and individual responses varied. The population and treatment duration are necessary to interpret each percentage.

As a calculation example, 15% of a starting weight of 200 pounds is 30 pounds. Your own response may differ substantially from a trial average. The appropriate treatment goal also considers blood pressure, glucose where relevant, mobility, and other health outcomes.

Zepbound begins at 2.5 mg weekly for four weeks, then increases to 5 mg. The starting dose is not an approved maintenance dose. Later increases are in 2.5 mg steps after at least four weeks at the current dose. Weight-treatment maintenance options are 5, 10, or 15 mg weekly, selected according to response and tolerability.

The schedule gives time to assess nausea, bowel changes, food intake, and hydration. Report persistent or severe symptoms before another increase. If weight has stabilized, review adherence, current benefit, nutrition, and other medicines with the clinician. Taking a larger amount or shortening the interval can increase harm.

Zepbound is prescribed with a reduced-calorie diet and increased physical activity. Meals may become smaller, but you still need enough nutrition and fluids. Regularly being unable to eat, repeated vomiting, marked weakness, or dehydration should trigger a review.

Ask for dietary support when digestive effects, existing kidney disease, diabetes treatment, or an eating-disorder history make meal planning difficult. Agree on activity that suits your health and ability. Review strength and daily function alongside weight so the plan supports normal life.

In SURMOUNT-4, participants who completed a 36-week tirzepatide lead-in were randomized to continue treatment or switch to placebo for another year. From the randomization weight, the continuing group lost a further 5.5% on average, while the placebo group gained 14.0%. Diet and activity support continued. The trial included people who had completed the initial treatment period, so its results need that context.

The 2026 SURMOUNT-MAINTAIN trial also studied continued high-dose treatment, reduction to 5 mg, and discontinuation after an initial weight-loss period. Continuing treatment better maintained weight reduction; the lower-dose group also did better than placebo on average. This supports individualized maintenance discussion, with dose reduction considered by the clinician when appropriate.

Before an interruption, discuss cost, duration, pregnancy plans, and the plan for follow-up. A previous dose may need reconsideration after a gap. Keep the actual last dose and administration date available when transferring care.